The Phase 1b safety clearance and biomarker data are incremental positives but lack efficacy readouts. The mid-2027 data catalyst is distant; near-term stock movement likely driven by broader sentiment on TPD space and cash runway updates.
Price Chart
Executive Summary
C4 Therapeutics presented biomarker data at IMS 2026 showing cemsidomide activates T cells and prevents exhaustion in RRMM. The Phase 1b combination trial with elranatamab cleared the 75 µg dose as safe and is advancing to dose escalation and expansion cohorts. Full Phase 1b data are expected in mid-2027.
Key Facts
- Biomarker data from Phase 1 trial of cemsidomide + dexamethasone in 62 heavily pre-treated RRMM patients showed coordinated T-cell activation and NK cell reprogramming.
- Phase 1b trial of cemsidomide + elranatamab cleared 75 µg dose as safe; advancing to 100 µg dose escalation and 75 µg expansion cohorts.
- Data from first two Phase 1b patients showed cemsidomide drives CD8+ effector memory T-cell expansion and prevents exhaustion (PD-1, TIM-3, LAG3).
- Full Phase 1b data from all cohorts expected in mid-2027.
Financial Impact
No financial data provided; clinical-stage company with no approved products or revenue.
Risk Factors
- Phase 1b data are from only two patients; small sample limits generalizability.
- Mid-2027 data timeline is long; no near-term binary catalysts.
- Cemsidomide is investigational; clinical failure or safety issues in larger cohorts could halt development.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3369035 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 8-K | $2.98 $2.95 | ▼ −1.01% | ▼ −0.79% | $3.21 (+7.72%) |
Sep 25, 2026 4w ago | Press Release | $2.98 $2.95 | ▼ −1.01% | ▼ −0.79% | $3.21 (+7.72%) |
Aug 14, 2026 10w ago | 144 | $4.27 $4.10 | ▼ −3.87% | ▼ −2.68% | $3.21 (−24.74%) |
Aug 14, 2026 10w ago | Institutional Cluster | $4.27 $4.10 | ▼ −3.87% | ▼ −2.68% | $3.21 (−24.74%) |
Aug 11, 2026 11w ago | 8-K | $3.87 $4.18 | ▲ +8.01% | ▲ +8.41% | $3.21 (−17.05%) |
Jun 11, 2026 19w ago | Press Release | $3.87 $3.92 | ▲ +1.29% | ▲ +0.86% | $3.21 (−17.05%) |
May 15, 2026 23w ago | 8-K | $3.22 $3.49 | ▲ +8.39% | ▲ +6.77% | $3.21 (−0.31%) |
May 12, 2026 24w ago | 8-K | $3.17 $3.22 | ▲ +1.58% | ▲ +1.50% | $3.21 (+1.26%) |
May 12, 2026 24w ago | Press Release | $3.17 $3.22 | ▲ +1.58% | ▲ +1.50% | $3.21 (+1.26%) |
Apr 9, 2026 28w ago | 8-K | $2.83 $2.90 | ▲ +2.47% | ▼ −0.71% | $3.21 (+13.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers